Novo Nordisk As
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$71Mgeneral payments (2019-2025)
$11Mresearch payments (2019-2025)
2,330clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Victoza $95K associated (2023-2025)
- Saxenda $79K associated (2023-2025)
- Rybelsus $43K associated (2023-2025)
- Ozempic $38K associated (2023-2025)
- Novoseven $20K associated (2023-2025)
- Sogroya $6,400 associated (2023-2025)
- Tresiba $6,000 associated (2023-2025)
- Fiasp $775 associated (2023-2025)
- Norditropin $95.00 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Andrew Cheng | South San Francisco, CA | Internal Medicine | $55,070,139.51 |
| Seth Harrison | New York, NY | $3,667,592.00 | |
| Carlo Traverso | Boston, MA | Gastroenterology (Internal Medicine) | $389,569.25 |
| Mazen Noureddin | Houston, TX | Gastroenterology (Internal Medicine) | $292,725.10 |
| Athena Philis-Tsimikas | La Jolla, CA | Endocrinology, Diabetes & Metabolism | $291,917.95 |
| Julio Rosenstock | Dallas, TX | Endocrinology, Diabetes & Metabolism | $280,421.45 |
| Mikhail Kosiborod | Kansas City, MO | Cardiovascular Disease | $229,756.50 |
| Matthew Cavender | Chapel Hill, NC | Interventional Cardiology | $227,015.35 |
| Vanita Aroda | Boston, MA | Endocrinology, Diabetes & Metabolism | $224,337.66 |
| Richard Pratley | Orlando, FL | Endocrinology, Diabetes & Metabolism | $205,437.22 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.